Medtronic, a global leader in healthcare technology, today released the three-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to-head comparative trial of transcatheter aortic valve replacement (TAVR). In patients with aortic stenosis (AS) and a small aortic annulus, results showed all individual and composite hemodynamic measures continue to be superior at three years for Evolut™ TAVR compared to SAPIEN™. The science was presented [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.